<DOC>
	<DOC>NCT02078752</DOC>
	<brief_summary>To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.</brief_summary>
	<brief_title>A Study Of PF-06647263 In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The clinical study will include 2 parts. Part 1 will estimate the MTD in dose escalation cohorts in patients with advanced solid tumors for whom no standard therapy is available in order to establish the RP2D. Part 2 will include patients with previously treated metastatic triple negative breast cancer (TNBC).</detailed_description>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for whom no standard therapy is available Performance Status of 0 or 1 Adequate bone marrow, kidney, and liver function Part 2 includes advanced triple negative breast cancer patients. Brain metastases requiring steroids Major surgery, radiation therapy, or systemic anticancer therapy within 4 weeks of study treatment start Active and clinically significant bacterial, fungal or viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ADC</keyword>
	<keyword>PF-06647263</keyword>
	<keyword>solid tumors</keyword>
	<keyword>tumors</keyword>
	<keyword>neoplasm metastasis</keyword>
	<keyword>TNBC</keyword>
	<keyword>Triple negative breast cancer</keyword>
</DOC>